"
Team:Virginia/Applications
From 2013.igem.org
| Line 257: | Line 257: | ||
<span>Current Applications Projects</span> | <span>Current Applications Projects</span> | ||
<p><b>Polysialic Acid</b></p> | <p><b>Polysialic Acid</b></p> | ||
| - | <img src=" | + | <img src="https://static.igem.org/mediawiki/2013/d/d7/Polysialicacidvgem.png" width="800"> |
<p>The K1 strain of E. coli produces and encapsulates itself in α-2,8-linked polysialic acid (PSA), a polysaccharide that biochemically mimics the human glycoprotein Neural Cell Adhesion Molecule (NCAM). This similarity renders virulent K1 E. coli poorly immunogenic in humans because they aren’t seen as foreign and are therefore cloaked from antibody opsonization and complement-mediated killing. Clearly, equipping our minicells with such protection would be highly advantageous for improving their successful delivery rate and reducing harmful immune responses. </p> | <p>The K1 strain of E. coli produces and encapsulates itself in α-2,8-linked polysialic acid (PSA), a polysaccharide that biochemically mimics the human glycoprotein Neural Cell Adhesion Molecule (NCAM). This similarity renders virulent K1 E. coli poorly immunogenic in humans because they aren’t seen as foreign and are therefore cloaked from antibody opsonization and complement-mediated killing. Clearly, equipping our minicells with such protection would be highly advantageous for improving their successful delivery rate and reducing harmful immune responses. </p> | ||
| - | <img src=" | + | <img src="https://static.igem.org/mediawiki/2013/c/cb/Group_2_capsules.png" width="800"> |
<p>A significant amount of machinery (14 genes in total) is required to generate the PSA capsule in K1 E. coli and transferring this ability over to the comparatively docile K12 E. coli is quite the feat. Thankfully, we were able to find previous work by Dr. Eric Vimr that accomplished just that and obtain a single pSR23 plasmid that contains all the required genes. We are currently in the process of confirming the presence of PSA on our K12 E. coli via antibody-labeled fluorescence microscopy. </p> | <p>A significant amount of machinery (14 genes in total) is required to generate the PSA capsule in K1 E. coli and transferring this ability over to the comparatively docile K12 E. coli is quite the feat. Thankfully, we were able to find previous work by Dr. Eric Vimr that accomplished just that and obtain a single pSR23 plasmid that contains all the required genes. We are currently in the process of confirming the presence of PSA on our K12 E. coli via antibody-labeled fluorescence microscopy. </p> | ||
</div> | </div> | ||
| Line 265: | Line 265: | ||
<span>Future Applications</span> | <span>Future Applications</span> | ||
<p><b>Targeting</b></p> | <p><b>Targeting</b></p> | ||
| - | <img src=" | + | <img src="https://static.igem.org/mediawiki/2013/thumb/2/27/Minicell_cancer_drug.png/800px-Minicell_cancer_drug.png " width="800"> |
<p>Previous researchers who have worked on minicells have attached Protein A/G Fc receptors to an OmpA autotransporter located on the surface of minicells. This patented approach allowed them to add antibodies specific to their target host cell to purified minicells, thereby creating targeted minicells. Additionally, the antibody coating serves to protect the minicells from the host immune system and induce endocytosis when binding to certain target cell receptors. Such a modular targeting system is ideal for such a versatile vector. We hope to create a similar system that allows our minicells utilize the vast library of commercial antibodies available as highly specific receptors for a variety of applications. </p> | <p>Previous researchers who have worked on minicells have attached Protein A/G Fc receptors to an OmpA autotransporter located on the surface of minicells. This patented approach allowed them to add antibodies specific to their target host cell to purified minicells, thereby creating targeted minicells. Additionally, the antibody coating serves to protect the minicells from the host immune system and induce endocytosis when binding to certain target cell receptors. Such a modular targeting system is ideal for such a versatile vector. We hope to create a similar system that allows our minicells utilize the vast library of commercial antibodies available as highly specific receptors for a variety of applications. </p> | ||
<p>Sources: | <p>Sources: | ||
Revision as of 14:59, 26 September 2013
Polysialic Acid
The K1 strain of E. coli produces and encapsulates itself in α-2,8-linked polysialic acid (PSA), a polysaccharide that biochemically mimics the human glycoprotein Neural Cell Adhesion Molecule (NCAM). This similarity renders virulent K1 E. coli poorly immunogenic in humans because they aren’t seen as foreign and are therefore cloaked from antibody opsonization and complement-mediated killing. Clearly, equipping our minicells with such protection would be highly advantageous for improving their successful delivery rate and reducing harmful immune responses.
A significant amount of machinery (14 genes in total) is required to generate the PSA capsule in K1 E. coli and transferring this ability over to the comparatively docile K12 E. coli is quite the feat. Thankfully, we were able to find previous work by Dr. Eric Vimr that accomplished just that and obtain a single pSR23 plasmid that contains all the required genes. We are currently in the process of confirming the presence of PSA on our K12 E. coli via antibody-labeled fluorescence microscopy.
Targeting
Previous researchers who have worked on minicells have attached Protein A/G Fc receptors to an OmpA autotransporter located on the surface of minicells. This patented approach allowed them to add antibodies specific to their target host cell to purified minicells, thereby creating targeted minicells. Additionally, the antibody coating serves to protect the minicells from the host immune system and induce endocytosis when binding to certain target cell receptors. Such a modular targeting system is ideal for such a versatile vector. We hope to create a similar system that allows our minicells utilize the vast library of commercial antibodies available as highly specific receptors for a variety of applications.
Sources:
